UMHAT " Tcaritca Yanna - ISUL"
Sofia, 1000, Bulgaria
NCT Number: NCT07770958
This prospective observational study will investigate whether circadian disruption is associated with higher blood pressure and a less favorable cardiovascular profile in young adults aged 18 to 45 years with essential arterial hypertension. Participants will undergo 14 days of wrist actigraphy using the CamNtech MotionWatch 8, 24-hour ambulatory blood pressure monitoring, cardiovascular assessment, laboratory testing, and validated questionnaires assessing perceived stress and insomnia symptoms. Circadian disruption will be classified using a predefined five-component research index based on actigraphy measures. Participants with three or more abnormal circadian indicators will be classified as Circadian Disruption Index-positive and compared with participants with zero to two abnormal indicators. The primary outcome is mean 24-hour systolic blood pressure. Secondary outcomes include nocturnal blood pressure patterns, cardiac structure and function, heart-rate variability, stress, insomnia symptoms, and individual circadian measures. The Circadian Disruption Index is a study-specific research classification and is not intended to diagnose a circadian rhythm sleep-wake disorder.
This study is active but is not currently recruiting participants.
Notify Me18 year–45 year
All sexes
Observational
Sofia, 1000, Bulgaria
This study is designed to investigate the relationship between circadian organization, sleep-wake patterns, and cardiovascular characteristics in young adults with established essential arterial hypertension. The study is based on the hypothesis that circadian disruption may be associated with an adverse cardiovascular phenotype, particularly alterations in the 24-hour blood pressure profile and early markers of cardiovascular remodeling.
Circadian organization will be assessed using prolonged ambulatory wrist actigraphy. A predefined research index will integrate five complementary indicators of circadian rhythmicity and sleep-wake regularity. The index is intended to provide an operational and reproducible classification of the degree of circadian disruption within the study population rather than to establish a clinical diagnosis of a circadian rhythm sleep-wake disorder.
Cardiovascular assessment will include ambulatory blood pressure monitoring, echocardiographic assessment of cardiac structure and function, heart-rate variability, and selected metabolic and inflammatory biomarkers. Psychological and sleep-related factors will also be assessed in order to explore the potential contribution of perceived stress and insomnia symptoms to the relationship between circadian organization and cardiovascular characteristics.
The primary analytical approach will compare participants classified as having a positive Circadian Disruption Index with those classified as negative. Multivariable statistical models will subsequently be used to determine whether the observed association between circadian disruption and cardiovascular parameters persists after adjustment for relevant demographic, anthropometric, hypertension-related, treatment-related, and sleep-related factors.
An additional exploratory objective is to evaluate whether a combination of cardiovascular, metabolic, behavioral, and psychological characteristics can identify participants with a higher probability of circadian disruption. This exploratory analysis may contribute to the development of a preliminary cardiovascular-circadian risk metric that could subsequently be evaluated and validated in independent cohorts.
The study is observational and does not assign participants to a therapeutic intervention. The research classification of circadian disruption should not be interpreted as a diagnosis of a circadian rhythm sleep-wake disorder, and the findings will be interpreted in the context of the overall clinical characteristics of the participants.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: During the 14-day actigraphy period
Mean systolic blood pressure over a valid 24-hour ambulatory blood pressure monitoring period performed during the 14-day actigraphy recording period.
Time frame: During the 14-day actigraphy period
Mean diastolic blood pressure over a valid 24-hour ambulatory blood pressure monitoring period.
Time frame: During the 14-day actigraphy period
Mean systolic blood pressure during the predefined nocturnal period measured by 24-hour ambulatory blood pressure monitoring.
Time frame: During the 14-day actigraphy period
Mean diastolic blood pressure during the predefined nocturnal period measured by 24-hour ambulatory blood pressure monitoring.
Time frame: During the 14-day actigraphy period
Percentage reduction in mean nocturnal systolic blood pressure compared with mean daytime systolic blood pressure.
Time frame: During the 14-day actigraphy period
Proportion of participants demonstrating a non-dipping or reverse-dipping nocturnal systolic blood pressure pattern based on 24-hour ambulatory blood pressure monitoring.
Time frame: At baseline assessment
Left ventricular mass indexed to body surface area, assessed by transthoracic echocardiography.
Time frame: At baseline assessment
Left atrial volume indexed to body surface area, assessed by transthoracic echocardiography.
Time frame: At baseline assessment
Ratio of early transmitral flow velocity to early diastolic mitral annular velocity as an echocardiographic measure of left ventricular diastolic function.
Time frame: At baseline assessment
Left ventricular global longitudinal strain assessed by transthoracic echocardiography.
Time frame: During the 14-day actigraphy period
Heart rate variability assessed using standard time-domain parameters, including SDNN and RMSSD.
Time frame: At baseline assessment
Perceived psychological stress was assessed using the 10-item Perceived Stress Scale (PSS-10). Each item is rated on a 5-point scale from 0 (never) to 4 (very often), yielding a total score of 0-40. Higher scores indicate greater perceived stress.
Time frame: At baseline assessment
Severity of insomnia symptoms was assessed using the Insomnia Severity Index (ISI), a 7-item questionnaire assessing difficulties with sleep onset, sleep maintenance, early morning awakening, satisfaction with sleep, interference with daily functioning, noticeability of sleep problems, and distress caused by sleep difficulties. Each item is scored from 0 to 4, yielding a total score of 0-28, with higher scores indicating greater insomnia severity. Scores of 0-7 indicate no clinically significant insomnia, 8-14 subthreshold insomnia, 15-21 moderate clinical insomnia, and 22-28 severe clinical insomnia.
Time frame: During the 14-day actigraphy period
Interdaily Stability (IS) derived from actigraphy to quantify the consistency of the 24-hour activity-rest pattern across monitoring days.
Time frame: During the 14-day actigraphy period
Intradaily Variability (IV) derived from actigraphy to quantify fragmentation of the activity-rest rhythm within individual days.
Time frame: During the 14-day actigraphy period
Relative Amplitude (RA) derived from actigraphy as a measure of the contrast between the most active and least active periods of the 24-hour cycle.
Time frame: During the 14-day actigraphy period
Variability in sleep-onset time across the 14-day actigraphy monitoring period, expressed as the standard deviation of sleep-onset time.
Time frame: During the 14-day actigraphy period
Variability in wake time across the 14-day actigraphy monitoring period, expressed as the standard deviation of wake time.
Medical University of Sofia
Other
Prospective Observational Study Of Circadian Disruption And Cardiovascular Risk In Young Adults With Arterial Hypertension
Acronym: CIRCA-HT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06608472
Cardiovascular Diseases, Essential Arterial Hypertension
View Trial DetailsNCT04927299
Cardiovascular Diseases, Essential Arterial Hypertension
Mexico City, Mexico
View Trial DetailsNCT06205628
Cardiovascular Diseases, Essential Hypertension
Adelaide, South Australia, Australia
View Trial DetailsNCT02649426
Cardiovascular Diseases, Essential Hypertension
Birmingham, Alabama, United States
View Trial Details